[引用][C] 供者淋巴细胞输注对恶性血液病异基因造血干细胞移植后复发的治疗作用

肖毅, 刘文励 - 内科急危重症杂志, 2005

[PDF][PDF] Juvenile myelomonocytic leukemia

C Kratz, C Niemeyer - Hematology, 2005 - Taylor & Francis
Juvenile myelomonocytic leukemia (JMML) is a rare clonal myeloproliferative disorder
(MPD) of early childhood [1]. The median age at diagnosis is 2 years [1]. There is a male …

[HTML][HTML] Трансплантация гемопоэтических стволовых клеток при ювенильном миеломоноцитарном лейкозе: анализ опыта одного центра и обзор литературы

МА Масчан, ЛА Хачатрян, ЮВ Скворцова… - …, 2011 - cyberleninka.ru
Аллогенная трансплантация гемопоэтических стволовых клеток (ТГСК) стандарт
терапии пациентов с ювенильным миеломоноцитарным лейкозом (ЮММЛ). В статье …

[引用][C] 非血缘异基因造血干细胞移植治疗幼年型粒-单核细胞型白血病一例并文献复习

雷玉芳, 符粤文, 王倩, 刘生全, 周健, 房佰俊, 喻凤宽… - 白血病. 淋巴瘤, 2013

Allogeneic stem cell transplantation in children with leukemia using human leukocyte antigen‐mismatched unrelated donors

P Sedlacek, R Formankova, E Mejstrikova… - Pediatric …, 2008 - Wiley Online Library
Allogeneic HSCT is a curative treatment, when chemotherapy fails, for certain malignant
diseases. In Europe, only 15% of the indicated children have an HLA‐matched sibling …

[HTML][HTML] Cytosine arabinoside and mitoxantrone followed by second allogeneic transplant for the treatment of children with refractory juvenile myelomonocytic …

SA Patel, DW Coulter, AC Grovas… - Journal of pediatric …, 2014 - journals.lww.com
Hematopoietic stem cell transplantation (HSCT) remains the only curative option for most
patients with juvenile myelomonocytic leukemia (JMML). However, persistent disease and …

Stem cell transplant as an immunomodulatory tool for children with hematologic malignancies

JL LaBelle, JM Cunningham - American Society of Clinical Oncology …, 2013 - ascopubs.org
Allogeneic stem cell transplantation (alloHSCT) is the most common and effective form of
immunotherapy used for treatment of pediatric leukemias. A combination of graft …

Allo-SCT in children with high-risk leukemia using unmanipulated grafts from alternative donors

P Sedlacek, E Mejstrikova, R Formankova… - Bone Marrow …, 2008 - nature.com
Allogeneic HSCT is a curative treatment for high-risk leukemia. In Europe, approximately
15% of children have an HLA-matched sibling, but in 65–70% HLA allele-matched (9 …

[HTML][HTML] Donor KIR Gene Content and KIR-Ligand Matching and Outcomes of Pediatric Patients with JMML Following Unrelated Donor Transplant

HG Rangarajan, MSF Pereira… - … and cellular therapy, 2021 - ncbi.nlm.nih.gov
Background: Natural killer (NK) cell determinants predict relapse-free survival after
allogeneic hematopoietic cell transplant (HCT) for acute myeloid leukemia, and prior studies …

[HTML][HTML] Juvenile Myelomonocytic Leukemia Treatment (PDQ®)

PDQPTE Board - PDQ Cancer Information Summaries [Internet], 2024 - ncbi.nlm.nih.gov
This PDQ cancer information summary for health professionals provides comprehensive,
peer-reviewed, evidence-based information about the treatment of juvenile myelomonocytic …